

Product datasheet for **TL306531V**

Asporin (ASPN) Human shRNA Lentiviral Particle (Locus ID 54829)

Product data:

| | |
|---------------|--|
| Product Type: | shRNA Lentiviral Particles |
| Product Name: | Asporin (ASPN) Human shRNA Lentiviral Particle (Locus ID 54829) |
| Locus ID: | 54829 |
| Synonyms: | OS3; PLAP-1; PLAP1; SLRR1C |
| Vector: | pGFP-C-shLenti (TR30023) |
| Format: | Lentiviral particles |
| Components: | ASPN - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml. |
| RefSeq: | NM_001193335 , NM_017680 , NM_017680.1 , NM_017680.2 , NM_017680.3 , NM_017680.4 , NM_001193335.1 , BC063114 , BC063114.1 , BC022059 , NM_001193335.2 |
| UniProt ID: | Q9BXN1 |
| Summary: | This gene encodes a cartilage extracellular protein that is member of the small leucine-rich proteoglycan family. The encoded protein may regulate chondrogenesis by inhibiting transforming growth factor-beta 1-induced gene expression in cartilage. This protein also binds collagen and calcium and may induce collagen mineralization. Polymorphisms in the aspartic acid repeat region of this gene are associated with a susceptibility to osteoarthritis, and also with intervertebral disc disease. Alternative splicing of this gene results in multiple transcript variants.[provided by RefSeq, Jul 2014] |
| shRNA Design: | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service . |



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).